Last reviewed · How we verify
New formulation EMB-001 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
New formulation EMB-001 (New formulation EMB-001) — Embera NeuroTherapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| New formulation EMB-001 TARGET | New formulation EMB-001 | Embera NeuroTherapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- New formulation EMB-001 CI watch — RSS
- New formulation EMB-001 CI watch — Atom
- New formulation EMB-001 CI watch — JSON
- New formulation EMB-001 alone — RSS
Cite this brief
Drug Landscape (2026). New formulation EMB-001 — Competitive Intelligence Brief. https://druglandscape.com/ci/new-formulation-emb-001. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing